IMPORTANCE Many studies have considered the association between Medicare spending and health outcomes at a point in time; few have considered the association between the long-term growth in spending and outcomes.

OBJECTIVE To assess whether components of growth in Medicare expenditures are associated with mortality rates between January 1, 1999, and June 30, 2014, for beneficiaries hospitalized for acute myocardial infarction.

DESIGN, SETTING, AND PARTICIPANTS Cross-sectional analysis of a random 20% sample of fee-for-service Medicare beneficiaries from January 1, 1999, through December 31, 2000 (n=72,473) and January 1, 2004, through December 31, 2004 (n=38,248), and 100% sample from January 1, 2008, through December 31, 2008 (n=159,558) and January 1, 2013, through June 30, 2014 (n=209,614) admitted with acute myocardial infarction to 1,220 hospitals.

MAIN OUTCOMES AND MEASURES Primary exposure measures include the growth of 180-day expenditure components (eg, inpatient, physician, and postacute care) and early percutaneous coronary intervention by hospitals adjusted for price differences and inflation. The primary outcome is the risk-adjusted 180-day case fatality rate.

RESULTS Patients in each of the years 2004, 2008, and 2013-2014 (relative to those in 1999-2000) were qualitatively of equivalent age, less likely to be white or female, and more likely to be diabetic (all P < .001). Adjusted expenditures per patient increased 13.9% from January 1, 1999, through December 31, 2000, and January 1, 2013, through June 30, 2014, but declined 0.5% between 2008 and 2013-2014. Mean (SD) expenditures in the 5.0% of hospitals (n = 61) with the most rapid expenditure growth between 1999-2000 and 2013-2014 increased by 44.1% ($12,828 [$2315]); for the 5.0% of hospitals with the slowest expenditure growth (n = 61), mean expenditures decreased by 18.7% (−$7384 [$4141]; 95% CI, $8177-$6496). The growth in early percutaneous coronary intervention exhibited a negative association with 180-day case fatality. Spending on cardiac procedures was positively associated with 180-day mortality, while postacute care spending exhibited moderate cost-effectiveness ($455,000 per life saved after 180 days; 95% CI, $323,000-$833,000). Beyond spending on noncardiac procedures, growth in other components of spending was not associated with health improvements.

CONCLUSIONS AND RELEVANCE Health improvements for patients with acute myocardial infarction varied across hospitals and were associated with the diffusion of cost-effective care, such as early percutaneous coronary intervention and, to a lesser extent, postacute care, rather than overall expenditure growth. Interventions designed to promote hospital adoption of cost-effective care could improve patient outcomes and, if accompanied by cuts in cost-ineffective care (inside and outside of the hospital setting), also reduce expenditures.
With potential cuts in federal support for health insurance, the question of how these spending reductions might adversely affect population health is of particular importance. There is little agreement regarding the association between health care expenditures and outcomes, with estimates ranging from large and positive to 0 or negative. Although it is well understood that not all spending is cost-effective, nearly all studies have summarized the multidimensional components of patient care by a single dollar measure—total expenditures—rather than considering how the money is spent (ie, for cost-effective or ineffective services).

To address these knowledge gaps, we use a large longitudinal patient-level database from the Medicare fee-for-service population of elderly patients admitted to the hospital for acute myocardial infarction (AMI) between January 1, 1999, and June 30, 2014. Based on previous evidence documenting differential rates of spending growth across the United States, we hypothesized that hospitals have experienced different patterns of growth (or even decline) in treatment intensity for patients with AMI, with some hospitals investing most heavily in postacute care and others focusing on increasing the use of early percutaneous coronary interventions (PCIs), other cardiac procedures, imaging, or physician services.

We further hypothesized that risk- and inflation-adjusted growth in total Medicare spending is not the most important determinant of overall health outcomes, but that the components of spending growth, whether on cost-effective or cost-ineffective services, should have a greater impact on health outcomes. We therefore consider, separately, the association between the change in health outcomes from 1999 through 2014 and the diffusion of several treatment modalities during the same period, including those previously found to be cost-effective (ie, early PCI1,11) and those less supported by evidence,12,13 such as testing and imaging, physician visits, cardiac and noncardiac procedures, outpatient care, and postacute care (including skilled nursing facilities, home health agencies, hospice, and durable medical equipment).

Methods

This study was approved by the Dartmouth institutional review board. Given the retrospective nature of this study, participant informed consent was not required.

Data

We used a random 20% sample of Medicare beneficiaries for 1999, 2000, and 2004, and a 100% sample for 2008, 2013, and 2014 (through June 30, 2014). To increase statistical power in smaller hospitals, we combined 2 years of data for both January 1, 1999, through December 31, 2000, and January 1, 2013, through June 30, 2014, when calculating changes. Eligible patients were fee-for-service Medicare enrollees with the primary diagnosis of AMI based on appropriate diagnosis codes from the *International Classification of Diseases, Ninth Revision* (410.xx [except 410.x2]), during each year.

Key Points

**Question** What is the association between growth in Medicare expenditures and decreased mortality between January 1, 1999, and June 30, 2014?

**Findings** In this cross-sectional analysis study of Medicare beneficiaries with acute myocardial infarction, reductions in mortality varied by hospital and were associated with diffusion of cost-effective care, such as early percutaneous coronary interventions, rather than overall spending.

**Meaning** Increased adoption of cost-effective care at the hospital level could improve patient outcomes and, if accompanied by cuts in cost-ineffective care (whether in the acute care or postacute care setting), may also reduce expenditures.

The sample included those (1) enrolled in Medicare (Part A and Part B, as identified through the Medicare denominator file) for the entire year beyond their index admission (or until the month of their death), (2) aged at least 65 years at the time of their index admission, and (3) enrolled in a non–health maintenance organization plan for at least 1 month during each of the 12-month periods. Data from the Medicare provider analysis and review files were linked to other files (carrier file, home health agency, durable medical equipment, outpatient, and hospice) containing claims that represented services associated with the patient’s index admission and subsequent services (and expenditures) for a 180-day period following admission. Outpatient claims include bills from rehabilitation facilities, hospital outpatient departments, and other institutional outpatient health care providers.

We excluded patients admitted to a non–acute care hospital with a primary diagnosis of AMI, those transferred to an acute care hospital with a primary diagnosis other than AMI, and those discharged alive and not transferred with a total length of stay of 1 day or less. We defined a transfer as occurring if the date of discharge was the same as the date of admission between 2 mutually exclusive hospitals. The total length of stay for the index admission was defined from the date of admission to discharge, including any transfers.

**Primary Outcome**

The primary outcome measure is the risk-adjusted 180-day case fatality (or mortality) rate. In the sensitivity analysis, we also considered the risk-adjusted 30- to 180-day (conditional on surviving 30 days) case fatality rates.

**Calculation of Exposure Variables**

We report price-standardized Medicare payments for the index admission and postindex utilization up to 180 days following the initial admission date. Standardized payments adjust for differences across regions in Medicare reimbursement rates for services attributed to costs of living, graduate medical education, and disproportionate-share hospital payments. Annual spending is converted to 2014 dollars after adjustment for general inflation, using the chain-weighted gross domestic product price deflator. Spending measures calculated at 180 days were conditional on survival to 180 days.
Hospital Payments
Hospital payments included those associated with the acute index hospitalization (diagnosis related group payment plus outlier payments when present) and other hospitalizations occurring within 180 days of the initial admission date. Expenditures included actual payments to health care professionals, absent amounts billed to patients or their supplemental insurance policies.

Physician Payments and Utilization
We provide utilization and payments for physician services based on Current Procedural Terminology and Berenson-Eggers Type of Service (BETOS) codes. Through these codes, we identified utilization of PCI and coronary artery bypass grafting (CABG) surgery. The BETOS codes create clinically relevant service categories for analyzing payments (eg, testing and imaging, physician visits, and cardiac and noncardiac procedures).

Other Expenditures After the Index Hospitalization
We included expenditures for skilled nursing facilities, outpatient services, home health agencies, hospice, and durable medical equipment.

Statistical Analysis
The analysis was performed at the individual patient level for 1999, 2000, 2004, 2008, 2013, and 2014. Logistic regressions, restricted to hospitals appearing in all years and treating at least 10 patients hospitalized with AMI per year, were used to estimate the models, with marginal probability estimates (using the “margin dydx( ), atmeans” command in Stata version 14.0 Statistical Software [StataCorp LP] ) reported in the tables and with standard errors clustered at the hospital referral region level appearing in parentheses (using the “cluster (hrr)” command in Stata version 14.0).

We used 2 types of exposure measures, calculated at the hospital level. Our first exposure was based on overall 180-day price- and inflation-adjusted expenditures dollar levels. Given that marginal health benefits may vary according to how money is spent, we further stratified spending into 6 categories: (1) testing and imaging, (2) physician visits, (3) cardiac procedures, (4) other procedures, (5) hospital care based on Medicare Part A spending, and (6) postacute care (with further breakdown into skilled nursing facility, home health, hospice, and durable medical equipment). Components of physician spending were categorized using BETOS codes.

The second exposure focused on utilization for a highly effective AMI treatment: the share of patients receiving PCI on the first day of the index hospitalizations for AMI (early PCI). To understand whether PCI substituted for other types of services, we also assessed whether changes in early PCI rates were associated with changes in 180-day spending and 180-day CABG surgery.

To account for differences across patients (and over time) in underlying health status, we adjusted for the beneficiary’s age, sex, race/ethnicity, and Charlson comorbidity index (presence of vascular disease, pulmonary disease, asthma, dementia, diabetes mellitus, liver and renal disorders, and cancer). To adjust further for potential confounding, we measured hospital-level exposure rates for those surviving the entire 180 days after index hospitalization.

Table 1. Characteristics of Patients and Care Provided to Medicare Beneficiaries Admitted for Acute Myocardial Infarctions, 1999-2014

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Proportion, Mean (SE)</th>
<th>1999-2000 (20% Sample) (72,473)</th>
<th>2004 (20% Sample) (38,248)</th>
<th>2008 (100% Sample) (159,558)</th>
<th>2013-2014 (100% Sample) (209,614)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Demographic</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age groups, y</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>65-74</td>
<td>0.38 (0.49)</td>
<td>0.36 (0.48)</td>
<td>0.36 (0.48)</td>
<td>0.40 (0.49)</td>
<td></td>
</tr>
<tr>
<td>75-84</td>
<td>0.42 (0.49)</td>
<td>0.41 (0.49)</td>
<td>0.39 (0.49)</td>
<td>0.36 (0.48)</td>
<td></td>
</tr>
<tr>
<td>≥85</td>
<td>0.20 (0.40)</td>
<td>0.22 (0.42)</td>
<td>0.26 (0.44)</td>
<td>0.25 (0.43)</td>
<td></td>
</tr>
<tr>
<td>Race</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>0.91 (0.29)</td>
<td>0.90 (0.30)</td>
<td>0.89 (0.31)</td>
<td>0.87 (0.33)</td>
<td></td>
</tr>
<tr>
<td>Black</td>
<td>0.06 (0.25)</td>
<td>0.07 (0.26)</td>
<td>0.07 (0.26)</td>
<td>0.08 (0.27)</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>0.03 (0.68)</td>
<td>0.03 (0.17)</td>
<td>0.03 (0.18)</td>
<td>0.05 (0.21)</td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>0.50 (0.50)</td>
<td>0.50 (0.50)</td>
<td>0.49 (0.50)</td>
<td>0.47 (0.50)</td>
<td></td>
</tr>
<tr>
<td>Comorbid conditions</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ischemic heart disease</td>
<td>0.45 (0.50)</td>
<td>0.48 (0.50)</td>
<td>0.42 (0.49)</td>
<td>0.43 (0.50)</td>
<td></td>
</tr>
<tr>
<td>Peripheral vascular disease</td>
<td>0.12 (0.32)</td>
<td>0.13 (0.33)</td>
<td>0.12 (0.33)</td>
<td>0.11 (0.32)</td>
<td></td>
</tr>
<tr>
<td>Cerebrovascular disease</td>
<td>0.12 (0.32)</td>
<td>0.11 (0.31)</td>
<td>0.11 (0.31)</td>
<td>0.10 (0.30)</td>
<td></td>
</tr>
<tr>
<td>Diabetes</td>
<td>0.30 (0.46)</td>
<td>0.31 (0.46)</td>
<td>0.32 (0.47)</td>
<td>0.35 (0.48)</td>
<td></td>
</tr>
<tr>
<td>Mortality, d</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>30 and 31-180</td>
<td>0.27 (0.44)</td>
<td>0.25 (0.44)</td>
<td>0.24 (0.43)</td>
<td>0.22 (0.41)</td>
<td></td>
</tr>
<tr>
<td>30</td>
<td>0.17 (0.38)</td>
<td>0.15 (0.36)</td>
<td>0.14 (0.35)</td>
<td>0.12 (0.33)</td>
<td></td>
</tr>
<tr>
<td>31-180</td>
<td>0.11 (0.32)</td>
<td>0.12 (0.33)</td>
<td>0.12 (0.32)</td>
<td>0.10 (0.31)</td>
<td></td>
</tr>
</tbody>
</table>

*International Classification of Diseases, Ninth Revision codes are as follows: ischemic heart disease (428), peripheral vascular disease (440-448), cerebrovascular disease (430-438), and diabetes (250).

The 31- to 180-day rate is conditional on surviving the first 30 days.
We included hospital-level categorical variables to adjust for unmeasured differences in health status across hospitals that may otherwise bias our results.21,22 We included categorical variables for the admission year, to adjust for general trends and other unobservable confounding factors that evolve over time. Statistical analyses were performed using Stata version 14 and SAS version 9.4 (SAS Institute Inc) statistical software.

We additionally tested interaction terms for quartiles of AMI volume and early PCI utilization rates, and additionally by ST-elevation myocardial infarction (STEMI) vs non–ST–elevation myocardial infarction (NSTEMI) (eTable 1 in the Supplement). We also conducted sensitivity analyses (eAppendix in the Supplement).

### Results

We identified 479,893 Medicare beneficiaries who were hospitalized for an AMI (72,473 from the 20% sample of enrollees in 1999-2000, 38,248 from the 20% sample of enrollees in 2004, and 159,558 and 209,614 from the 100% samples in 2008 and 2013-2014, respectively).

As shown in Table 1, patients with AMI in 2004, 2008, and 2013-2014 (relative to those in 1999-2000) were qualitatively of equivalent older age (eg, >85%: 0.22 in 2004, 0.26 in 2008, 0.25 in 2013-2014 vs 0.20 in 1999-2000), less likely to be white (0.90, 0.89, 0.87 vs 0.91) or female (0.50, 0.49, 0.47 vs 0.50).
Overall, 180-day case fatality rates per patient with AMI declined from 26.9% in 1999-2000 to 21.5% in 2013-2014, with most of the decline attributed to the 30-day period. The rate for days 31 to 180 (among patients surviving for 30 days after an AMI) was relatively unchanged from 1999-2000 to 2013-2014.

Growth in Total 180-Day Medicare Expenditures
Overall inflation- and risk-adjusted 180-day mean expenditures per patient increased by 13.9% ($4486) between 1999-2000 and 2013-2014 (Table 2). All of the increase occurred by 2008, 14.5% ($4654), with a 0.5% decline in risk- and inflation-adjusted spending between 2008 and 2013-2014. Total spending grew 6.1% up to 30 days beyond the index admission, and 31.0% from 31 to 365 days beyond the index admission. There was considerable heterogeneity in 180-day growth rates across hospitals. Spending in the 61 hospitals (or 5% of all hospitals) with the slowest expenditure growth decreased 18.7% (−$7384; 95% CI, −$8177 to −$6496), while spending in the 61 hospitals with fastest expenditure growth grew 44.1% ($12 828; 95% CI, $12 084 to $13 890).

Spending on inpatient services per beneficiary grew by just $417 (1.8%) between 1999-2000 and 2013-2014, and median length of stay decreased by 2 days during the same period (P < .001). During this same period, physician and outpatient spending increased by $1582 (outpatient spending increased by $1818 per beneficiary); 44% of the change in physician and outpatient spending was associated with cardiac procedures (change in spending for cardiac procedures/change in physician and outpatient spending, $684), while hospital visits accounted for an additional 22% of spending (change in mean spending for hospital visits/change in physician and outpatient spending, $347).

Growth in PCI Rates and Decline in CABG Rates
Utilization of PCI through 180 days increased by 48.9% between 1999-2000 and 2013-2014 (mean, 0.309 vs 0.460, respectively), while early (same day as admission) PCI utilization increased by 102.9% (mean, 0.173 vs 0.351, respectively). Only 1.7% of patients with AMI were treated in hospital-years in which no other patient at the hospital received early PCI. Between 1999-2000 and 2013-2014, 180-day CABG rates decreased by 35.3% (mean, 0.167 vs 0.108, respectively). This latter finding may be explained by the fact that we restricted to hospitals with at least 11 patients with AMI every year.

We investigated whether hospitals that increased their early PCI use simultaneously decreased their use of other services. Changes in 180-day CABG rates were only weakly correlated with changes in early (r = −0.099) or 180-day (r = −0.164) PCI rates. We further decomposed the type of postacute care spending associated with growth in early PCI. We found that hospitals that increased their use of early PCI the most (ie, fourth quartile), relative to the lowest growth quartile, had lower 180-day per-beneficiary mean spending for skilled nursing facilities (−$700) as well as home health agency, hospice, and durable medical equipment (−$298) (eTable 2 in the Supplement).

Association Between Health Care Spending and Case Fatality Rates
Changes in 180-day spending were weakly associated with risk-adjusted case fatality, using either bivariate correlations at the hospital level (Figure 1) or multivariate regression analysis at the patient level (Table 3). However, changes in early PCI were strongly and inversely associated with 180-day case fatality (Figure 2). In multivariable analysis controlling for other measures of 180-day spending, early PCI rates were inversely associated with 180-day mortality (β = −0.079, P < .001) (Table 3). This finding was stronger among patients with STEMI (β = −0.172, P < .001) relative to those with NSTEMI (β = −0.0912, P < .001), and persisted even after controlling for CABG utilization (β = −0.078, P < .001) and other spending components (β = −0.078, P < .001) (eTable 3 in the Supplement). We found a significant interaction between quartiles of AMI volume and early PCI rates on 180-day mortality, whereby the greatest reductions in mortality attributed to early PCI were among those hospitals with the highest average AMI volume. This volume effect occurred solely among patients with NSTEMI (P = .008) (eTable 4 in the Supplement).

Increases in 180-day case fatality rate were associated positively with cardiac procedure spending (β = 0.004, P = .007), and negatively with postacute care (β = −0.002, P < .001), the latter of which translates to a cost-effectiveness ratio of $455 000 per life saved (95% CI, $323 000–$833 000) (Table 3). In a sensitivity analysis that examined the composition of postacute care spending (eTable 3 in the Supplement), only spending on skilled nursing facilities and early PCI rates exhibited significant negative associations with case fatality rates (P < .001). After holding early PCI rates constant, no other component of spending had a statistically significant association with 180-day fatality, including spending on physician visits.

changes in hospital rates of early percutaneous coronary interventions, performed within a day of admission. Solid line represents fitted values.

0.49, 0.47 vs 0.50), and more likely to be diabetic (0.31, 0.32, 0.35 vs 0.30 [all P < .001]).

Decline in Overall 180-Day Case Fatality
Overall, 180-day case fatality rates per patient with AMI declined from 26.9% in 1999-2000 to 21.5% in 2013-2014, with most of the decline attributed to the 30-day period. The rate for days 31 to 180 (among patients surviving for 30 days after an AMI) was relatively unchanged from 1999-2000 to 2013-2014.
Discussion

Overall inflation- and risk-adjusted 180-day expenditures per patient with AMI have increased by 14.4% since 1999-2000, yet this growth masks substantial variation in hospital spending growth. For example, the top 5.0% of hospitals in terms of growth rates (61 hospitals) averaged 44.1% increased growth rate during this period, while the bottom 5.0% of hospitals with the slowest expenditure growth decreased spending by 18.7%. Nonetheless, hospitals with more rapid increases in spending did not experience larger case fatality rate declines.

Spending growth occurred principally during 31 to 180 days following admission, with a doubling of nursing home and home health care expenditures. Beyond growth in postacute spending, outpatient services tripled, contributing importantly to 180-day spending increases. While use of noninvasive procedures by cardiologists grew between 1998 and 2008, our present data suggest imaging and testing mod-

Table 3. Association of Early PCI and Hospital Spending on 180-Day Acute Myocardial Infarction Mortality Ratesa,b

<table>
<thead>
<tr>
<th>Early PCI or Spending</th>
<th>Model 1, Full Sample (n=479 873)c</th>
<th>Model 2, Full Sample (n=479 873)d</th>
<th>Model 3, NSTEMI (n=331 635)e</th>
<th>Model 4, NSTEMI (n=331 635)</th>
<th>Model 5, STEMI (n=148 077)c</th>
<th>Model 6, STEMI (n=148 077)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Early PCI rate, No.</td>
<td>-0.068 (0.0094) e</td>
<td>-0.079 (0.0094) e</td>
<td>-0.080 (0.012) e</td>
<td>-0.0917 (0.0122) e</td>
<td>-0.155 (0.010)e</td>
<td>-0.172 (0.0099)e</td>
</tr>
<tr>
<td>P value</td>
<td>&lt; .001</td>
<td>&lt; .001</td>
<td>&lt; .001</td>
<td>&lt; .001</td>
<td>&lt; .001</td>
<td>&lt; .001</td>
</tr>
<tr>
<td>With $1000 increase in total spending</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>180-d Mortality</td>
<td>-0.0002 (0.0001)</td>
<td>-0.0002 (0.0001)</td>
<td>-0.0002 (0.0001)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P value</td>
<td>.04</td>
<td>.12</td>
<td>.10</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>180-d Testing</td>
<td>-0.0041 (0.0027)</td>
<td>.0027 (0.0028)</td>
<td>.0053 (0.0027)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P value</td>
<td>.13</td>
<td>.34</td>
<td>.05</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>180-d Visits</td>
<td>-0.0043 (0.0023)</td>
<td>-0.0061 (0.0023)</td>
<td>-0.0062 (0.0028)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P value</td>
<td>.06</td>
<td>.01</td>
<td>.03</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>180-d Cardiac procedures</td>
<td>0.0042 (0.0016)*</td>
<td>0.0049 (0.0017)*</td>
<td>0.0042 (0.0014)*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P value</td>
<td>.01</td>
<td>.003</td>
<td>.002</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>180-d Other procedures</td>
<td>-0.0042 (0.0017)</td>
<td>-0.0050 (0.0019)</td>
<td>-0.0050 (0.0016)*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P value</td>
<td>.02</td>
<td>.01</td>
<td>.002</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>180-d Part A</td>
<td>0.0002 (0.0003)</td>
<td>0.0002 (0.0001)</td>
<td>0.0006 (0.0001)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P value</td>
<td>.40</td>
<td>.50</td>
<td>.04</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>180-d Postacute care</td>
<td>-0.0022 (0.0005)*</td>
<td>-0.0016 (0.0005)*</td>
<td>-0.0042 (0.0006)*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P value</td>
<td>&lt; .001</td>
<td>.003</td>
<td>&lt; .001</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: NSTEMI, non-ST–elevation myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST-elevation myocardial infarction.

a Sample includes patients who visited hospitals that appeared in the data in all years and that treated at least 10 patients with acute myocardial infarction per year.
b Logit model estimated; marginal effects reported using “margins, dydx() atmeans” in Stata. All regressions control for patient characteristics, hospital fixed effects, and year fixed effects. All spending measures are calculated for each hospital-year using patients who live 6 months. Includes years 1999, 2000, 2004, 2008, 2013, and quarters 1 and 2 of 2014. Standard errors are clustered at the hospital level.

c P < .0125 for 5% significance level using Bonferroni correction; P < .005 for 1% significance level using Bonferroni correction.
d P < .0007 for 5% significance level using Bonferroni correction; P < .0014 for 1% significance level using Bonferroni correction.
e Statistical significance after conducting the Bonferroni correction.
focusing on the role of income on AMI mortality and hospitalizations, Spatz et al34 reported declines in AMI mortality among Medicare beneficiaries (irrespective of income level) over a 15-year period. Yet, this moderation in spending observed for patients with AMI masks substantial and continued hospital variability with regard to growth or declines in overall spending, suggesting that local factors and not just national policy changes continue to be important components of expenditure growth.

Second, policy makers seek to use bundled payments to incentivize coordination over care episodes, reduce spending, and maintain (or improve) quality.30 Prior work has highlighted postacute spending as a potential target for bundled payment programs.31 We found that spending was fairly well contained within 30 days after admission (6.1% inflation-adjusted increase in spending). The fixed diagnosis related group payment has likely contributed to reducing the length of stay by 2 days on average since 1999-2000. Most of the variation (in growth rates and variation therein) appears after 30 days. Given this finding, bundling payments to include services occurring beyond 30 days could further moderate expenditure growth.30

Limitations
Our study has several limitations. First, our study was limited to fee-for-service Medicare beneficiaries. While an increasing portion of Medicare beneficiaries are covered by private plans,32 the majority remain covered through a traditional fee-for-service plan. Second, investigators have identified other factors that may influence 180-day case fatality rates, including evidence-based medical therapies33 and changes over time in socioeconomic status; however, previous work suggests modest effects of socioeconomic status once other measures of health status are controlled for.34 Third, we did not have a full accounting of all spending components (eg, pharmaceutical, supplemental insurance bills). Fourth, some potentially important components of spending were not accounted for in the present analysis (eg, pharmaceuticals). Fifth, while postacute care spending beyond 30 days may not be directly managed by the index hospital, there is increased awareness and management of postacute care by health systems attributed in part to further dissemination of Accountable Care Organizations and bundled payment programs. Sixth, we cannot rule out temporal differences in NSTEMI diagnosis attributed to the rapid diffusion of cardiac biomarkers during this period. Another limitation is a focus on mortality only rather than quality of life, a measure that is unfortunately beyond the scope of our nationally representative Medicare claims data.

Conclusions
While minimal hospital variation existed in spending within the traditional 30-day episode-based reimbursement window, large variation in growth rates and treatment diffusion existed between 31 and 180 days beyond the index admission. Hospitals that increased early PCI use experienced improvements in health outcomes but did not experience large

---

**Figure 2. Change in 180-Day Risk-Adjusted Case Fatality vs Change in Early PCI Utilization for 2013-2014 vs 1999-2000**

Changes in 180-day risk-adjusted case fatality by hospital rates of early percutaneous coronary interventions performed within a day of admission. Solid line represents fitted values; PCI, percutaneous coronary intervention.

---

E7

© 2017 American Medical Association. All rights reserved.
overall cost increases. Policies encouraging hospitals to adopt early PCI, while supporting hospital-based and non-hospital-based reductions in spending on less cost-effective services (perhaps through newly designed bundled payment programs), may help improve patient outcomes without increasing costs.

ARTICLE INFORMATION

Accepted for Publication: October 31, 2017.
Published Online: December 20, 2017.

Author Affiliations: Department of Cardiac Surgery, University of Michigan, Ann Arbor (Likosky); Department of Economics, Hunter College, New York, New York (Van Parys); The Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine, Hanover, New Hampshire (Van Parys, Zhou, Skinner); Department of Medicine, George Washington University, Washington, DC (Borden); Department of Health Policy and Management, George Washington University, Washington, DC (Borden); the Department of Health Policy and Management, Harvard T. H. Chan School of Public Health, Boston, Massachusetts (Weinstein); Department of Economics, Dartmouth College, Hanover, New Hampshire (Skinner).

Author Contributions: Drs Likosky and Skinner had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Concept and design: Likosky, Van Parys, Borden, Weinstein, Skinner. Acquisition, analysis, or interpretation of data: Likosky, Van Parys, Zhou, Skinner. Drafting of the manuscript: Likosky, Van Parys, Zhou.


Conflict of Interest Disclosures: All authors have completed and submitted the ICJME Form for Disclosure of Potential Conflicts of Interest. Dr Borden serves as a consultant to the Agency for Healthcare Research and Quality on cardiovascular disease prevention, although his work on this study was unrelated to the Agency for Healthcare Research and Quality. Dr Weinstein serves as a consultant to OptumInsight. Dr Skinner serves as a director of the aging program at the National Bureau of Economic Research and is an investor in Dorata, Inc. No other disclosures are reported.

Funding/Support: This study was supported by Data Use Agreement S483 between the Centers for Medicare and Medicaid Research and Dartmouth College, grant P01-AG019783 from the National Institute on Aging, and grant U01AG046830 from the National Institutes of Health Common Fund. Dr Likosky was supported by grant HS-022535 from the Agency for Healthcare Research and Quality. Dr Borden was previously supported at Cornell University as a Nanette Laitman Clinical Scholar.

Role of the Funder/Sponsor: The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

REFERENCES


